- Home
- PMCB vs ACXP Comparison
PMCB vs ACXP Comparison
Compare PMCB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- ACXP
- Stock Information
- Founded
- PMCB 1996
- ACXP 2017
- Country
- PMCB United States
- ACXP United States
- Employees
- PMCB N/A
- ACXP N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- ACXP Health Care
- Exchange
- PMCB Nasdaq
- ACXP Nasdaq
- Market Cap
- PMCB 6.7M
- ACXP 6.8M
- IPO Year
- PMCB N/A
- ACXP 2021
- Fundamental
- Price
- PMCB $1.04
- ACXP $4.24
- Analyst Decision
- PMCB
- ACXP Strong Buy
- Analyst Count
- PMCB 0
- ACXP 3
- Target Price
- PMCB N/A
- ACXP $143.67
- AVG Volume (30 Days)
- PMCB 121.2K
- ACXP 89.0K
- Earning Date
- PMCB 09-15-2025
- ACXP 11-12-2025
- Dividend Yield
- PMCB N/A
- ACXP N/A
- EPS Growth
- PMCB N/A
- ACXP N/A
- EPS
- PMCB 0.01
- ACXP N/A
- Revenue
- PMCB N/A
- ACXP N/A
- Revenue This Year
- PMCB N/A
- ACXP N/A
- Revenue Next Year
- PMCB N/A
- ACXP N/A
- P/E Ratio
- PMCB $163.65
- ACXP N/A
- Revenue Growth
- PMCB N/A
- ACXP N/A
- 52 Week Low
- PMCB $0.80
- ACXP $3.80
- 52 Week High
- PMCB $2.42
- ACXP $43.20
- Technical
- Relative Strength Index (RSI)
- PMCB 52.01
- ACXP 51.39
- Support Level
- PMCB $0.94
- ACXP $3.97
- Resistance Level
- PMCB $1.06
- ACXP $4.85
- Average True Range (ATR)
- PMCB 0.08
- ACXP 0.35
- MACD
- PMCB 0.00
- ACXP -0.02
- Stochastic Oscillator
- PMCB 38.16
- ACXP 23.45
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.